Neogen Corporation stock fell 7.22% on Tuesday following FDA regulatory action concerning the recall of its HYCOAT equine product, sparking a new shareholder investigation.
Neogen Corporation shares experienced a significant decline of 7.22% following regulatory intervention by the FDA concerning the recall of its HYCOAT equine product. This negative market reaction has prompted a shareholder investigation into the company's handling of the product safety issue. The selloff occurred outside of the standard earnings cycle, as the company is not scheduled to report financial results until October 6, 2026.
The stock dropped 7.22% due to FDA action regarding the recall of the HYCOAT equine product.
The next earnings report is scheduled for October 6, 2026.
Neogen Corporation shares dropped 7.22% after the FDA took action regarding the company's recalled HYCOAT equine product. The sudden decline has prompted a shareholder investigation into the firm's regulatory compliance and disclosure practices.
The stock fell 7.22% due to FDA regulatory action involving the recall of the company's HYCOAT equine product.